Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) EBITDA Margin (2016 - 2025)

Myriad Genetics (MYGN) has disclosed EBITDA Margin for 17 consecutive years, with 2.72% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 1580.0% to 2.72% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 46.96% through Dec 2025, down 3223.0% year-over-year, with the annual reading at 46.96% for FY2025, 3222.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 2.72% at Myriad Genetics, up from 11.33% in the prior quarter.
  • The five-year high for EBITDA Margin was 2.72% in Q4 2025, with the low at 154.48% in Q2 2025.
  • Average EBITDA Margin over 5 years is 28.82%, with a median of 17.89% recorded in 2024.
  • The sharpest move saw EBITDA Margin surged 6230bps in 2021, then tumbled -13722bps in 2025.
  • Over 5 years, EBITDA Margin stood at 26.8% in 2021, then fell by -10bps to 29.36% in 2022, then soared by 46bps to 15.97% in 2023, then dropped by -16bps to 18.52% in 2024, then soared by 85bps to 2.72% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 2.72%, 11.33%, and 154.48% for Q4 2025, Q3 2025, and Q2 2025 respectively.